March 15, 2018

Poxel to Report Full Year 2017 Results on March 22, 2018 After Market Close and Host Conference Call at 7:00 PM CET (Paris time) / 2:00 PM EDT (New York time)

LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic diseases, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), announced today that it will report its financial results for full year 2017 on Thursday, March 22, 2018, at 5:45 PM CET (Paris time) / 12:45 PM EDT (New York time).

The management team will host a conference call at 7:00 PM CET, Paris time / 2:00 PM EDT, New York time, to review the financial results and provide a corporate update.

To access the conference call, please use one of the following dial-in numbers at least 5 minutes prior to the scheduled start time:
USA: +1 844-286-0643
UK: +44 (0) 20 71943759
FR: +33 (0)1 72 72 74 03
Followed by the PIN code**: 44674523#**

Following the conclusion of the live call, a replay will be available for 90 days. To access the replay, please use one of the following numbers:
USA: +1 646-722-4969
UK: +44(0) 2033645147
FR: +33 (0)1 70 71 01 60
The passcode for the replay is 418732208#

About Poxel SA
Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH). We have successfully completed the Phase 2 clinical program for our first-in-class lead product, Imeglimin, which targets mitochondrial dysfunction, in the U.S., EU and Japan. Together, with our partner Sumitomo Dainippon Pharma, we are conducting the Phase 3 TIMES program for the treatment of type 2 diabetes in Japan. Our partner Roivant Sciences will be responsible for Imeglimin's development and commercialization in countries outside of Poxel's partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe. Our second program, PXL770, a first in class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is in Phase 1 and we

plan on developing it for the treatment of NASH. We intend to generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxelpharma.com).

View source version on businesswire.com:
http://www.businesswire.com/news/home/20180315005876/en/

Poxel SA
Jonae R. Barnes, +1 617-818-2985
Senior Vice President, Investor Relations and Public Relations
jonae.barnes@poxelpharma.com
or
Investor relations / Media - EU/US
Trophic Communications
Gretchen Schweitzer, +49 89 238 877 34
or
Stephanie May, +49 171 185 56 82
may@trophic.eu
or
Investor relations / Media - France
NewCap
Florent Alba/Nicolas Merigeau, +33 1 44 71 98 55
poxel@newcap.fr

Source: Poxel SA